Functional characterization of the alanine-serine-cysteine exchanger of Carnobacterium sp AT7 by Bartoccioni, Paola et al.
RESEARCH ARTICLE
Functional characterization of the
alanine-serine-cysteine exchanger of Carnobacterium
sp AT7
Paola Bartoccioni1,2*, Joana Fort1,2,3*, Antonio Zorzano1,3,4, Ekaitz Errasti-Murugarren1, and Manuel Palaćın1,2,3
Many key cell processes require prior cell uptake of amino acids from the environment, which is facilitated by cell membrane
amino acid transporters such as those of the L-type amino acid transporter (LAT) subfamily. Alterations in LAT subfamily amino
acid transport are associated with several human diseases, including cancer, aminoacidurias, and neurodegenerative
conditions. Therefore, from the perspective of human health, there is considerable interest in obtaining structural information
about these transporter proteins. We recently solved the crystal structure of the first LAT transporter, the bacterial alanine-
serine-cysteine exchanger of Carnobacterium sp AT7 (BasC). Here, we provide a complete functional characterization of
detergent-purified, liposome-reconstituted BasC transporter to allow the extension of the structural insights into mechanistic
understanding. BasC is a sodium- and proton-independent small neutral amino acid exchanger whose substrate and inhibitor
selectivity are almost identical to those previously described for the human LAT subfamily member Asc-1. Additionally, we
show that, like its human counterparts, this transporter has apparent affinity asymmetry for the intra- and extracellular
substrate binding sites—a key feature in the physiological role played by these proteins. BasC is an excellent paradigm of
human LAT transporters and will contribute to our understanding of the molecular mechanisms underlying substrate
recognition and translocation at both sides of the plasma membrane.
Introduction
Amino acid availability regulates cellular physiology. The
transfer of amino acids across the plasma membrane is me-
diated by specific amino acid transporters. Heteromeric
amino acid transporters (HATs) comprise two subunits, a
polytopic membrane protein (the light subunit; SLC7 family)
and a disulfide-linked N-glycosylated type II membrane gly-
coprotein (the heavy subunit; SLC3 family; Fotiadis et al.,
2013). The light subunits of HATs belong to the L-type ami-
no acid transporter (LAT) subfamily, which is part of the large
amino acids, polyamines, and organic cations (APC) family of
transporters, and are the catalytic component of the trans-
porter (Reig et al., 2002). In contrast, the heavy subunit ap-
pears to be essential only for trafficking to the plasma
membrane. Two heavy subunits (4F2hc and rBAT) and eight
light subunits have been identified in humans (Fernández
et al., 2006).
Several human pathologies highlight the physiological roles
of HATs. Two transporters of this family are responsible for
inherited aminoacidurias, and mutations in either of the two
genes coding for the subunits of system b(0,+) (rBAT and b(0,+)AT)
lead to cystinuria (MIM 220100; Calonge et al., 1994;
Feliubadaló et al., 1999), while mutations in y+LAT1 (a 4F2hc-
associated system y+L) result in lysinuric protein intoler-
ance (LPI; MIM222700; Torrents et al., 1998; Borsani et al.,
1999). Additionally, mutations in LAT1 and LAT2 are asso-
ciated with autism and age-related hearing loss, respectively
(Tărlungeanu et al., 2016; Espino Guarch et al., 2018), and
Asc-1/CD98hc is a druggable target in schizophrenia as
it is the major D-serine transporter in brain, which acts as
a coagonist of NMDA glutamate receptors (Sakimura et al.,
2016). Moreover, xCT and LAT1 are overexpressed in
many human tumors, thereby suggesting that amino
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manuel.palacin@irbbarcelona.org.
© 2019 Bartoccioni et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the
publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0
International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
Rockefeller University Press https://doi.org/10.1085/jgp.201812195 505




 https://rupress.org/jgp/article-pdf/151/4/505/874001/jgp_201812195.pdf by guest on 12 June 2020
acid transporters are essential for tumor cell survival and
progression (del Amo et al., 2008; Lo et al., 2008; Savaskan
and Eyüpoglu, 2010). In this regard, two different anticancer
therapies involving both xCT and LAT1 have been proposed.
On the one hand, these transporters mediate the uptake of
several amino acid–derived anticancer drugs (del Amo et al.,
2008; Lo et al., 2008; Savaskan and Eyüpoglu, 2010). This
observation thus suggests that these proteins are involved in
the cellular internalization of these antineoplasic drugs. On
the other hand, a novel strategy based on the inhibition of
xCT and LAT1 activities has been described (Chung et al.,
2005; del Amo et al., 2008; Lo et al., 2008; Savaskan and
Eyüpoglu, 2010), thus reducing tumor proliferation and
progression. Targeting amino acid transporters in cancer
is conceptually novel since specific inhibitors are scarce.
In this regard, the development of drugs with greater ac-
tivity against these transporters is expected to challenge
the scene.
The atomic structures of plasma membrane transporter
proteins are the most powerful tools for the design of more
specific and active therapeutic molecules and for under-
standing substrate binding and translocation mechanisms.
Considerable homology with human amino acid transporters
may provide crucial insights into intelligent drug design for
the treatment of several cancers and neuronal diseases, as
well as knowledge of the effect of pathological mutations on
transporter protein activity (Morth et al., 2009; Wu et al.,
2014). To date, the atomic structure of a LAT transporter has
not been published. The closest available crystal structures
correspond to those of remote bacterial homologues (17–22%
sequence identity [SI]), namely the amino acid exchangers
AdiC and GadC, and the proton-coupled amino acid trans-
porters ApcT and GkApcT, which belong to the APC family of
transporters (Fang et al., 2009; Gao et al., 2009, 2010; Shaffer
et al., 2009; Kowalczyk et al., 2011; Ma et al., 2012; Ilgü et al.,
2016; Jungnickel et al., 2018). Nevertheless, the generation of
robust and reliable structural models of LAT transporters based
on these distant crystallized homologues is precluded by low
amino acid SI with human LAT (hLAT) transporters. In this
regard, an hLAT1 model based on a mixed sequence alignment
of AdiC and ApcT with hLAT1 has been reported as a tool to
identify structurally novel molecules of pharmacological in-
terest (Geier et al., 2013).
Close prokaryotic homologues have emerged as excellent
structural and functional paradigms of their human coun-
terparts (Penmatsa et al., 2013). In this regard, the serine/
threonine exchanger (SteT) was shown to be a good func-
tional homologue of hLAT (Reig et al., 2007). However, de-
spite significant efforts that have led to an increase in the
crystalizability of the protein, no crystal structure was ob-
tained (Rodrı́guez-Banqueri et al., 2016). We recently solved
the crystal structure of the first transporter of the LAT sub-
family (bacterial asc; BasC; unpublished data). Here we report
the complete functional characterization of BasC, showing
extremely similar functional features to those of hLAT, thus
making it a suitable protein for further studies on LAT sub-
family members.
Materials and methods
Identification and sequence analysis of prokaryotic
LAT transporters
To identify prokaryotic homologues of LAT subfamily trans-
porters, initial sequence analysis was performed using the
BLAST algorithm (default settings; Altschul et al., 1990) to
compare a prototypical hLAT transporter sequence (particularly
LAT1) against a nonredundant protein sequence database. Seven
bacterial sequences encoding for putative LAT transporters
sharing between 25% and 30% SI with LAT1 were selected for
protein expression and purification. Multi-sequence alignment
was done with the PSI/TM-Coffee server (Floden et al., 2016)
using the members of the APA (2.A.3.2), CAT (2.A.3.3), ABT
(2.A.3.6), GGA (2.A.3.7), and LAT (2.A.3.8) subfamilies of the
APC family (www.tcdb.org; Saier et al., 2016), and a phyloge-
netic tree was drawn by iTOL tool (Letunic and Bork, 2016).
Cloning of prokaryotic LAT transporters
Ecolized complementary DNAs encoding the seven selected
putative amino acid transporter proteins were obtained from
GenScript and subcloned into the EcoRI and PstI sites of a
modified PTTQ18 expression vector. A variant of a GFP, lacking
the start codon, was added in frame to the C terminus of the
transporter sequence. Additionally, the sequence of HRV-3C
protease was inserted between the transporter protein and GFP
sequences. Finally, four additional histidines were added to the
preexistent hexahistidine tag in the PTTQ18 vector. Single
point mutations were introduced using the QuikChange site-
directed mutagenesis kit (Agilent). All DNA constructs were
verified by sequencing. The A20C mutant was generated on a
cys-less mutant (C427A) background to finally generate the
double A20C-C427A mutant (referred to as A20C mutant) that
has been used to study the sidedness of the substrate inter-
action of BasC.
Protein expression of prokaryotic LAT transporters in
Escherichia coli
Expression experiments were performed with freshly trans-
formed cultures of E. coli strain BL21 Star (DE3). Initially, the
expression of all seven putative LAT transporters was studied in
50-ml samples cultured in Luria-Bertani medium containing
50 µg/ml ampicillin. When the absorbance measured at 600 nm
(A600) had reached 0.5, protein expression was induced at dif-
ferent isopropyl-β-D-thiogalactopyranoside (Roche) concen-
trations (0.1 mM, 0.5 mM, or 1 mM), incubation times, 4 h or
overnight, and temperatures (25°C, 30°C, or 37°C). To estimate
protein expression, GFP fluorescence was measured and protein
quantity calculated as previously reported (Drew et al., 2005).
The putative LAT transporter of Carnobacterium sp AT7 (BasC
hereafter) was identified as a stable protein species suitable for
crystallographic studies by application of fluorescence-detection
size exclusion chromatography (Drew et al., 2005). BasC was
overexpressed in E. coli BL21 Star (DE3) cells grown in Luria-
Bertani media as a C-terminal fusion with GFP. Expression was
induced by 0.1 mM isopropyl-β-D-thiogalactopyranoside at 37°C
for 22 h. Cells were harvested at 5,000×g for 15min and stored at
−80°C until use.
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Preparation of E. coli membranes
Cell pellets were thawed and resuspended in 20 mM Tris-Base,
150 mM NaCl, pH 7.4. Cells were pelleted again at 5,000×g for
15 min, resuspended in lysis buffer (20 mM Tris-Base, 350 mM
NaCl, pH 7.4, 1 mM Pefabloc, and complete mini protease in-
hibitor cocktail (Roche), and broken using a Cell Disruptor
(20,000 psi, four cycles; Constant Systems). Cell debris was
removed by centrifugation (1 h at 15,000×g, 4°C), and the su-
pernatant was subjected to ultracentrifugation (2 h at
200,000×g, 4°C). The membrane pellet was resuspended in
20 mM Tris-Base, 150 mM NaCl, pH 7.4, and 10% glycerol at a
protein concentration of between 8 and 12 mg/ml, frozen in
liquid nitrogen, and stored at −80°C until use.
Purification of prokaryotic LAT transporters
All subsequent steps were performed at 4°C. Membranes at
3 mg/ml protein concentration were solubilized using 1% (wt/
vol) n-dodecyl-β-D-maltopyranoside (DDM; Affymetrix) for 1 h
in purification buffer (20 mM Tris-Base, 150 mM NaCl, pH 7.4,
0.05% DDM, and 10% glycerol). After ultracentrifugation (2 h,
200,000×g, 4°C), the soluble fraction was incubated for 3 h at
4°C with equilibrated Ni2+–nitrilotriacetic acid (NTA) Superflow
beads (QIAGEN) with washing buffer (20 mM Tris-Base,
150 mM NaCl, pH 7.4, 0.05% DDM, 10% glycerol, and 20 mM
imidazole). Protein-bound beads were washed three times with
10 column volumes of washing buffer before elution with 15 ml
of elution buffer (washing buffer supplemented with 350 mM
imidazole). The purified protein was concentrated by centrifu-
gation in an Amicon Ultra (100,000 D molecular weight cut-off;
Millipore) at 3,220xg until reaching the desired protein con-
centration. To assess BasC quality and purity after Ni2+-NTA
purification, size exclusion chromatography (SEC) of GFP-fused
BasC was performed in a Superdex 200 10/300 GL (GE
Healthcare) in SEC buffer (20 mM Tris-Base, 150 mM NaCl, pH
7.4, and 0.05% DDM). AdiC was purified for functional studies as
previously described (Kowalczyk et al., 2011).
Reconstitution into proteoliposomes (PLs)
BasC and AdiC proteins were reconstituted in E. coli polar lipids
(Sigma-Aldrich), as previously described (Reig et al., 2007;
Kowalczyk et al., 2011). Lipid was dried under N2 and suspended
in reconstitution buffer (20mMTris-Base and 150mMNaCl, pH
7.4). The suspension was sonicated to clarity, and purified BasC
protein was added to the desired protein/lipid ratio (wt/wt; 1:
100). To destabilize the liposomes, 1.25% β-D-octylglucoside was
added and incubated in ice with occasional agitation for 5 min.
DDM and β-D-octylglucoside were removed by dialysis for 40 h
at 4°C against 100 volumes of dialysis buffer. PL suspensions
were used or frozen in liquid N2 and stored at −80°C until use.
Amino acid transport assays in PLs
For transport measurements, PLs were prepared as previously
described (Tsai et al., 2012). For uptake experiments, the desired
intracellular amino acid concentration was added to the PL
suspension, which was then subjected to three freeze–thaw
cycles. The extraliposomal amino acid content was then re-
moved by ultracentrifugation. Amino acid uptake assays were
initiated after mixing 10 µl of cold PLs with 180 µl of transport
buffer (20 mM Tris-Base and 150 mM NaCl, pH 7.4), 0.5–1 µCi/
data point of radiolabeled L-amino acid (PerkinElmer), and un-
labeled amino acid to the desired concentration, and this mix-
ture was then incubated at room temperature for the indicated
periods of time. Efflux measurements were performed by filling
the liposomes by three freeze–thaw cycles with transport buffer
plus 10 µM L-serine and 0.5 µCi/data point of [3H]L-serine. The
release of [3H]L-serine was measured by adding 180 µl of
transport buffer with or without 4 mM cold amino acid.
Transport experiments were stopped by the addition of 2 ml of
ice-cold stop buffer (5 mM L-serine in transport buffer) and
filtration through 0.45-µm pore sizemembrane filters (Sartorius
Stedim Biotech). Filters were then washed two times with 2 ml
of stop buffer and dried, and the trapped radioactivity was
counted. Transport measured in PLs containing no amino acid
was subtracted from each data point in order to calculate the net
exchange. Transport measurements are normalized to the BasC
protein concentration measured for each proteoliposome batch.
Saturation kinetics were evaluated by nonlinear regression
analysis, and the kinetic parameters derived from this method
were confirmed by linear regression analysis of the derived
Eadie–Hofstee plots. Data are expressed as the mean ± SEM of
three experiments performed on different days and on different
batches of protein and PLs.
Use of cysteine-modifying reagents
MTSES or MTSEA (Anatrace) were freshly prepared by dis-
solving the reagent in ice-cold water just before use. Liposomes
were then centrifuged and resuspended in fresh buffer (20 mM
Tris-Base and 150 mM NaCl, pH 7.4) and treated with 1–5 mM
MTSES or MTSEA for 15–60 min (as indicated) before [3H]L-
serine uptake or efflux measurements were performed. In la-
beling experiments, liposomes with BasC A20C mutant were
treated with HRV-3C protease (2 h at 4°C), adding 1 mMDTT and
0.5 mM EDTA to the buffer. Then, 1 mM Cy5-maleimide was
added (ON at 4°) after 1–5 mM MTSES or MTSEA treatment for
60 min. In-gel fluorescence was detected by Odyssey Fc (Bonsai
Advanced Technologies) at 600 nm (GFP) and 700 nm (Cy5).
N-His–tagged HRV-3C protease was obtained from the Institute
for Research in Biomedicine Barcelona Protein Expression Core
Facility.
Online supplemental material
Fig. S1 shows BasC sequence alignment with human LATs. Ad-
ditionally, mutated residues associated with autism (LAT1), age-
related hearing loss (LAT2), cystinuria (b(0+)AT), and LPI
(y+LAT1) are also highlighted. Fig. S2 shows that cysless BasC
L-serine/L-alanine exchange activity in PLs is not affected by
cysteine-modifying reagents MTSES and MTSEA.
Results
To identify a suitable prokaryotic candidate for the structure–
function analysis of LAT transporters, BLAST analysis on hLAT1
sequence retrieved a number of candidates with SIs ranging
from 25 to 30%. The seven bacterial putative amino acid
Bartoccioni et al. Journal of General Physiology 507
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transporters with higher SI were expressed as a GFP-fused
version, thus analyzing protein expression, detergent solubili-
zation efficiency, and stability by means of GFP fluorescence
(data not shown). As a result, a putative amino acid transporter
(BasC hereafter) from Carnobacterium sp AT7was selected due to
its high yield of purified protein (up to 10 mg/liter of bacterial
culture), high stability, and monodisperse behavior in DDM, as
shown by SEC (Fig. 1 A).
In a wide phylogenetic study of the APC superfamily of
transporters, sequence comparisons and the constructed phy-
logenetic tree indicated that BasC clustered with all of the
members of the LAT subfamily (Fig. 2). BasC contains 434 amino
acid residues that can be aligned in their entirety with almost
the full length of the sequences of hLAT transporters, in contrast
to the crystallized distant hLAT homologues AdiC, ApcT, and
GadC (Fang et al., 2009; Gao et al., 2009, 2010; Shaffer et al.,
2009; Kowalczyk et al., 2011; Ma et al., 2012; Ilgü et al., 2016;
Fig. 2 and Fig. S1) that have been the structural paradigms of the
hLAT transporter subfamily until now. Very recently, the
atomic structure of a prokaryotic homologue of the cationic
amino acid transporters subfamily belonging to the SLC7 family
has been solved (Jungnickel et al., 2018). This new transporter,
named GkApcT, has been shown to be an excellent model of
eukaryotic cationic amino acid transporters, but a distant one to
the LAT transporters both in sequence and function (Jungnickel
et al., 2018). Indeed, BasC presents 26–28% of SI to the core of
human LATS (LAT1, LAT2, y+LAT1, y+LAT2, Asc-1, b0,+AT, and
xCT), whereas GkApcT shows 18–22% SI to these human LATs.
Additionally, mapping of the pathogenic mutations found in
various LAT transporters, such as LAT1 in autism, y+LAT1 in LPI,
b(0+)AT in cystinuria, and LAT2 in age-related hearing loss
(Font-Llitjós et al., 2005; Sperandeo et al., 2008; Tărlungeanu
et al., 2016; Espino Guarch et al., 2018), showed that 62.8% of
these residues are conserved or semi-conserved in BasC (Fig. S1),
compared with 41.0%, 46.1%, 51.3%, and 53.1% in GadC, ApcT,
AdiC, and GkApcT, respectively. The main differences between
BasC and hLATs are shorter N and C termini in the former and
the absence of the cysteine residue in the loop between TM3 and
TM4 that is involved in the disulfide bridge between the light
and the heavy subunits in metazoan LAT transporters.
To assess BasC transport characteristics, C-terminally GFP-
His10–tagged BasC (BasC-GFP) was overexpressed in E. coli, and
DDM-solubilized protein was purified with a single immobilized
metal affinity chromatography step. Purified BasC-GFP ran as a
single and monodisperse peak in size exclusion chromatogra-
phy, its purity and identity being confirmed by Coomassie
blue–stained gels and in gel fluorescence (Fig. 1, A and B). Pu-
rified BasC-GFP was reconstituted in the presence of E. coli lipids
to form PLs (BasC-GFP-PLs) at a protein/lipid ratio of 1:100. SDS-
PAGE analysis of the resulting PLs revealed a single band at the
same molecular weight as the protein purified in detergent so-
lution (Fig. 1 B), thereby confirming incorporation of the protein.
Because BasC was an orphan transporter, to identify BasC
transport activity, the influx of 10 µM [3H]L-serine (SteT sub-
strate) or [3H]L-arginine (AdiC substrate) was thenmeasured. In
the presence of [3H]L-serine, but not [3H]L-arginine, BasC-GFP-
PLs showed higher transport in PLs filled with a mixture of 10
representative cold amino acids (at 1 mM each) than in the
empty ones (i.e., trans-stimulation; Fig. 3 A). Additionally,
10 µM [3H]L-serine accumulation inside empty BasC-GFP-PLs
was identical to that observed for both empty AdiC-PLs and
empty transporter-free liposomes (Fig. 3 A, inset). 10 µM [3H]L-
serine transport was then examined over time in BasC-GFP-PLs
containing 4 mM L-serine or no amino acid. BasC showed ac-
cumulation of [3H]L-serine over the equilibrium levels, as in-
dicated by the overshoot observed in L-serine–containing BasC-
GFP-PLs, which was not observed in the empty BasC-GFP-PLs
(Fig. 3 B).
Nevertheless, BasC was a fast [3H]L-serine/L-serine ex-
changer, the uptake being barely linear below 5 s (Fig. 3 B, inset).
Due to this experimental drawback, we decided to analyze [3H]
L-serine uptake over time in BasC-PLs containing 4 mM of in-
dividual amino acids. Thus, 10 µM [3H]L-serine/4 mM L-alanine
exchangewas demonstrated to be linear until 5 s (Fig. 3 C, inset).
As expected, 10 µM [3H]L-serine in exchange with 4 mM
L-alanine showed an overshoot, not observed in empty PLs
(Fig. 3 C). The peak of the overshoot (62 pmol L-serine/µg
protein) represents ∼5 molecules of substrate per the estimated
number of binding sites of BasC in the assay. This corresponds to
an accumulation of ∼100 µM L-serine inside BasC-PLs (internal
volume: 0.62 µl/µg protein), which represents ∼10-fold versus
the 10 µM [3H]L-serine in the medium and 12-fold versus
equilibrium conditions (360 min). The uptake of radiolabeled
L-serine in BasC-GFP-PLs filled with 4 mM L-alanine at 4 s was
considered ideal working conditions for further transporter
Figure 1. BasC purification and reconstitution in PLs. (A) SEC of DDM-
solubilized Ni2+-NTA purified BasC-GFP protein. mAUs, milli absorbance
units. (B) Coomassie blue–stained gel and in-gel fluorescence of purified
BasC. Purification of His-tagged BasC-GFP by nickel affinity chromatography
with or without a further SEC step. Coomassie blue–stained (left) and in-gel
fluorescence (right) SDS-PAGE (12% polyacrylamide gel) of the different
purification steps is shown: Ni2+-NTA purified BasC-GFP (lane 1), BasC re-
constituted in PLs (lane 2), and SEC-purified BasC (lane 3). BasC-GFPmigrates
as a prominent band at ∼50 kD.
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characterization. Similarly to the influx of 10 µM radiolabeled
L-serine in exchange with 4 mM L-alanine, efflux of 10 µM ra-
diolabeled L-serine from preloaded BasC-GFP-PLs was dramat-
ically trans-stimulated by the presence of L-serine in the
external medium, thereby demonstrating that BasC is a bidi-
rectional obligate exchanger (Fig. 3 D).
Given that several APC transporters are exchangers that are
active over a range of pHs, we explored various external proton
concentrations at a fixed internal pH value of 7.4. BasC-
GFP–mediated 10 µM [3H]L-serine/L-alanine exchange was op-
timal between pH 7.0 and 9.4, being strongly reduced at both
acidic and highly basic pHs (Fig. 4 A).We observed [3H]L-serine/
L-alanine exchange at all the external proton concentrations
assayed, this exchange being dependent exclusively on the
presence of amino acid substrate inside PLs. No 10 µM [3H]L-
serine uptake was observed at any external pH value in empty
PLs (Fig. 4 B). Moreover, BasC exchange activity was indepen-
dent of Na+, K+, and Cl− in the external medium (Fig. 4 C).
The substrate selectivity of BasC was studied initially using a
competition assay, in which the exchange of 10 µM [3H]L-serine
with 4 mM L-alanine inside BasC-GFP-PLs was measured in the
presence of 4 mM nonlabeled amino acids and derivatives in the
external medium. [3H]L-serine uptake was strongly inhibited by
small neutral amino acids (glycine, L-alanine, L-serine, L-thre-
onine, and L-cysteine) and L-asparagine, while acidic, aromatic
(except tryptophan) as well as proline and glutamine, did not
inhibit [3H]L-serine uptake (Fig. 5 A). Consistent with these
results, high uptake levels of [3H]L-serine were observed in
BasC-GFP-PLs containing 4 mM small neutral amino acids (and
significant for those containing L-asparagine), whereas negli-
gible levels of uptake were detected for the rest of the amino
acids assayed (Fig. 5 A). Valine, leucine, isoleucine, methionine,
tryptophan, and basic L–amino acids had significant inhibitory
effects on BasC-mediated [3H]L-serine uptake. Surprisingly, no
[3H]L-serine uptake was observed in BasC-GFP-PLs containing
4 mM of these amino acids (Fig. 5 A). In this regard, exchange of
either 10 µM or 100 µM [3H]L-isoleucine in 4 mM L-alanine
containing BasC PLs was negligible (data not shown). On the
other hand, 4 mM D-serine, D-threonine, D-cysteine, and
D-alanine exerted strong inhibitory effects on [3H]L-serine/
L-alanine exchange, but only D-serine trans-stimulated this
uptake at a similar rate as that achieved by L-serine (Fig. 5 B).
Additionally, experiments in which 10 µM [3H]L-serine/L-ala-
nine exchange was measured in the presence of 4 mM of com-
pounds structurally related to alanine revealed that alanine
methyl ester and 2-aminoisobutyric acid (AIB) strongly in-
hibited serine uptake, while N-methylalanine, methyl AIB, sar-
cosine, and γ-aminobutyric acid (GABA) did not inhibit BasC-
mediated [3H]L-serine/L-alanine exchange (Fig. 5 C). In agree-
ment, 4 mM alanine methyl ester and 4 mM 2-AIB trans-
stimulated 10 µM [3H]L-serine uptake, although at different
rates. Additionally, [3H]L-serine/L-alanine exchange was unaf-
fected by system L-specific inhibitor 2-aminobicyclo-(2,2,1)-
heptane-2-carboxylic acid (BCH) (Fig. 5 C). Given that the sub-
strate and inhibitor selectivity highly resembled that of the
human and mouse (Fukasawa et al., 2000; Brown et al., 2014)
alanine-serine-cysteine exchanger (Asc-1), we proposed that
this new prokaryotic LAT be named BasC (bacterial alanine-
serine-cysteine exchanger).
The kinetics of [3H]L-serine/L-alanine or [3H]L-alanine/
L-serine exchange in BasC-GFP-PLs were examined by varying
L-serine concentrations outside and inside the PLs, respectively.
Radiolabeled [3H]L-serine (up to 1.5 mM)/4 mM L-alanine ex-
change was saturable but showed a complex kinetics, suggesting
more than one component of transport (Fig. 6 A). A good fit to
one-component Michaelis–Menten kinetics was obtained when
the range of [3H]L-serine concentrationswas set up to 250 µM in
exchange with 4 mM L-alanine inside BasC-GFP-PLs. In these
conditions, the estimated Km values of L-serine measured from
outside were 45 ± 5 µM with a Vmax value of 6.0 ± 0.2 pmol [3H]
L-serine/µg BasC protein · s (Fig. 6 A). In contrast to the kinetics
from outside PLs, the kinetics varying the L-serine concentra-
tion inside the liposomes (up to 10 mM) in exchange with 10 µM
[3H]L-alanine in the external medium showed a good fit to one-
component Michaelis–Menten kinetics with a Km of 2.5 ±
0.4 mM from inside the BasC-PLs (Fig. 6 B). Similar values for
Figure 2. Phylogenetic relationships of BasC with other prokaryotic and eukaryotic members of the APC family. The neighbor-joining tree shows the
phylogenetic relationships of BasC with human members of the LAT subfamily, within the APC family, and the crystallized prokaryotic members of the APC
family. The tree was performed using all the alignable member sequences within the APC family present in the Transporter Classification Database (www.tcdb.org).
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the external and internal Km and Vmax were obtained with non-
GFP-tagged BasC reconstituted in PLs (Fig. 7).
As expected for a “ping-pong” mechanism of exchange, the
Km values for L-serine estimated from outside the liposomes,
using the conditions indicated above, were constant, indepen-
dently of the concentration of L-alanine inside the liposomes
(Fig. 6 C). Moreover, the Km for L-alanine inside the liposomes
estimated with the Vmax values of this seriated experiment re-
vealed again a Km in the mM range (1.5 ± 0.2 mM; Fig. 6 D). In all,
these experiments suggest that BasC reconstituted in liposomes
shows two components of transport with different apparent
affinities.
We next address whether these two components correspond
to different apparent affinities for the substrate at the extra-
cellular and intracellular sides of BasC. Indeed, BasC-GFP is
inserted randomly into the PLs as the arginine/agmatine ex-
changer AdiC (Tsai et al., 2012). This was evidenced by the
partial cleavage of GFP by HRV-3C protease from outside the
PLs. Because GFP is fused to the C terminus (intracellular side),
the cleaved BasC corresponds to the inside-out inserted trans-
porters (Fig. 8 A). To address whether the apparent high-affinity
component would correspond to the extra- or intracellular sides
of the transporter, we used a strategy similar to that previously
reported to study the sidedness of substrate interaction in AdiC
(Tsai et al., 2012). We used BasC-GFP A20C mutant in an oth-
erwise BasC cysless background (BasC-A20C-GFP). This mutant
is homologous to the mutant S26C in AdiC, in which residue Cys
26 is only accessible from the extracellular side. Similarly, Cys
20 in BasC is also only accessible from the extracellular side.
Thus, BasC-A20C-GFP PLs were treated with HRV-3C protease
to cleave GFP from the inside-out oriented transporter mole-
cules as in Fig. 8 A. Then, the sample was pretreated with 1 mM
MTSES (nonpermeable sulfhydryl-reagent) or with 5 mM
MTSEA (permeable sulfhydryl-reagent; Fig. 8 B) to block Cys20
residue. Then, the permeable Cy5-maleimide reagent was added
to covalently bind the fluorophore to nonblocked cysteine
Figure 3. Functional characterization of BasC reconstituted into E. coli liposomes. (A) 10 µM [3H]L-serine (1 µCi/µl) or [3H]L-arginine (1 µCi/µl) influx
(pmol/µg protein · s) into BasC-GFP-PLs containing a mixture of 10 representative amino acids (L-Arg, L-Orn, Gly, L-Pro, L-Ala, L-Leu, L-Met, L-Phe, L-Tyr, and
L-Glu at 1 mM each; black bars) or no amino acid (gray bars). Inset: 10 µM [3H]L-serine (1 µCi/µl) uptake (pmol/µg protein · s) in empty BasC-PLs, AdiC-PLs or
E. coli polar lipid liposomes. Data (mean ± SEM) are from three experiments with three replicates per condition. (B) Time course (0–360 min) of 10 µM [3H]L-
serine influx (pmol/µg protein) into BasC-GFP-PLs containing 4 mM L-serine (closed circles) or no amino acid (closed squares). Inset: Time course (0–10 s) of
10 µM [3H]L-serine/4 mM L-serine exchange (pmol/µg protein). Data correspond to a representative experiment, performed using three replicates. A second
independent experiment gave similar results. (C) Time course (0–360 min) of 10 µM [3H]L-serine influx (pmol/µg protein) into BasC-GFP-PLs containing 4 mM
L-alanine (closed circles) or no amino acid (closed squares). Inset: Time course (0–10 s) of 10 µM [3H]L-serine/4 mM L-alanine exchange (pmol/µg protein).
Data correspond to a representative experiment, performed using three replicates. A second independent experiment gave similar results. (D) Comparison of
10 µM [3H]L-serine (1 µCi/data point) influx (left) and 10 µM [3H]L-serine (1 µCi/data point) efflux (right) in BasC-GFP-PLs, expressed in pmol/µg protein · s.
Efflux measurements were performed by filling the liposomes by three freeze–thaw cycles with transport buffer plus 10 µM L-serine and 1 µCi/data point of
[3H]L-serine. The release of [3H]L-serine was measured by adding 180 µl of transport buffer to the BasC-GFP-PL suspension with or without 4 mM cold amino
acid. Efflux of radiolabeled L-serine was dramatically stimulated by the presence of L-serine in the external medium. Data (mean ± SEM) are from three
experiments with three replicates per condition.
Bartoccioni et al. Journal of General Physiology 510




 https://rupress.org/jgp/article-pdf/151/4/505/874001/jgp_201812195.pdf by guest on 12 June 2020
residues. Pre-treatment with MTSES did not block Cy5 labeling
of the inside-out oriented BasC-A20C molecules (i.e., BasC
with GFP cleaved out), indicating that MTSES reached residue
A20C only from the extracellular face of BasC (Fig. 8 B). As
expected, the permeable reagent MTSEA almost completely
abolished Cy5 labeling of Cys 20 (Fig. 8 B). Thus, Cys 20 in
inside-out inserted BasC molecules is not accessible from
outside the PLs.
Next we address the sidedness of the substrate apparent af-
finities of BasC taking advantage of the vectorial inactivation by
MTSES of the BasC-A20C-GFP activity. Fortunately, this mutant
retained significant transport activity (∼20% of BasC-GFP; 0.35 ±
0.08 and 1.84 ± 0.15 pmol [3H[L-serine/µg protein · s in the
mutant and wild-type BasC for 10 µM [3H]L-serine/4 mM
L-alanine exchange, respectively). Treatment of PLs of BasC-
A20C-GFP with 1 mMMTSES (impermeable) fully inhibited the
influx of 10 µM [3H]L-serine, but not its efflux, in exchangewith
4 mM L-alanine in the trans-side (Fig. 9, A and B). In contrast,
treatment of BasC-A20C-GFP PLs with 5 mM MTSEA (permea-
ble) resulted in complete inhibition of both 10 µM [3H]L-serine
influx and efflux in exchange with 4 mM L-alanine (Fig. 9, A and
B). As expected, 10 µM [3H]L-serine/4 mM L-alanine exchange
in PLs reconstituted with cysless BasC-GFP was not affected by
either MTSES or MTSEA treatment (Fig. S2). These results in-
dicate that the side of BasC-A20C-GFP showing detectable
transport of 10 µM [3H]L-serine (i.e., the apparent high-affinity
side) is accessible to the nonpermeant reagent (MTSES) and
therefore corresponds to the extracellular side of BasC.
To finally support this asymmetry of the substrate interac-
tion of BasC, the external kinetics of the [3H]L-serine (up to
1 mM; outside)/4 mM L-alanine (inside) exchange by BasC-
A20C-GFP was performed before and after treatment with 1 mM
MTSES (Fig. 9, C and D). As expected, nontreated BasC-A20C-
GFP PLs showed a complex extracellular kinetics for [3H]L-
serine/4 mM L-alanine exchange with a component of apparent
high affinity (Km for L-serine: 35 ± 2.8 µM) and another of ap-
parent low affinity. In contrast, MTSES-treated PLs did not show
the extracellular apparent high-affinity component. In these
conditions and due to the low activity of A20C mutant, the low-
affinity Km could not be determined because of the low signal/
background ratio at high L-serine concentrations. In all, these
results support that BasC has asymmetric interaction with
substrates, being the extracellular face of apparent high affinity
(Km in the µM range) and the intracellular face of apparent low
affinity (Km in the mM range) for substrates. Indeed, this is
similar to human LATs (Meier et al., 2002).
Discussion
HATs are gaining relevance as their essential physiological role
joins the increasing number of mutations associated with sev-
eral diseases (Feliubadaló et al., 1999; Sperandeo et al., 2008;
Tărlungeanu et al., 2016; Espino Guarch et al., 2018). Further-
more, in recent years it has been shown that the pharmacolog-
ical inhibition of some of these transporters provides an
effective strategy for the treatment of some types of cancer
(Chung et al., 2005; del Amo et al., 2008; Lo et al., 2008;
Savaskan and Eyüpoglu, 2010). However, knowledge of the ef-
fects of deleterious mutations on the structure or function of
these transporters, as well as the generation of specific target
drugs, has been greatly hindered by the lack of structural in-
formation. In this regard, only structures of distant homologues
both in sequence (18–22% SI) and function have been solved
(Fang et al., 2009; Gao et al., 2009; Kowalczyk et al., 2011; Ma
et al., 2012; Ilgü et al., 2016; Jungnickel et al., 2018).
Figure 4. Effect of external pH and salts on BasC activity. (A) 10 µM [3H]
L-serine (1 µCi/µl) influx into BasC-GFP-PLs containing 4 mM L-alanine at
different pHs. Internal pH was maintained at 7.4 while external pH was
changed (5.4–11.4). Transport was expressed as the percentage of [3H]L-
serine transport, considering 100% the highest [3H]L-serine uptake value
obtained. Data are from three experiments with three replicates per condi-
tion. (B) 10 µM [3H]L-serine (1 µCi/µl) influx (pmol/µg protein · s) into BasC-
GFP-PLs containing no amino acid and at different pHs. Internal pH was
maintained at 7.4 while external pH was changed (5.4–8.4). We observed
[3H]L-serine exchange in all the assayed external proton concentrations, this
exchange being dependent solely on the internal amino acid concentration.
No significant increase in [3H]L-serine uptake was observed at any external
pH value in empty PLs. Data (mean± SEM) are from three experiments with
three replicates per condition. (C) Effect of ions on BasC activity. Uptake of
10 µM [3H]L-serine (1 µCi/µl) into BasC-PLs containing 4 mM L-alanine was
performed in uptake buffer (20 mM Tris-Base and 150 mM NaCl, pH 7.4).
NaCl was then replaced by 150 mM of either choline chloride (ChoCl), po-
tassium chloride (KCl), or potassium acetate (KAc), and radiolabeled serine
uptake was measured. Transport was expressed as the percentage of
transport in BasC-GFP-PLs containing 4 mM L-alanine in uptake buffer with
NaCl. Data are from three experiments with three replicates per condition.
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Some years ago, we cloned, expressed, and purified SteT, the
L-serine/L-threonine antiporter of Bacillus subtilis, the first
prokaryotic member of LATs to be characterized (Reig et al.,
2007). For this reason, SteT emerged as a good bacterial para-
digm of LATs. Nevertheless, although a great deal of effort in
recent years has been channeled into improving SteT stability
(Rodŕıguez-Banqueri et al., 2016), crystallization assays have
failed to render results, thus fueling the search for a new pro-
karyotic paradigm suitable for atomic structure determination.
The crystal structure of BasC (unpublished data) is the only
high-resolution structural information available for the LAT
subfamily of transporters. The present study reports on the
functional reconstitution and characterization of BasC to iden-
tify those features shared with other LAT members: (1) phylo-
genetic analysis clustered the BasC amino acid sequence with
those of LAT family members within the APC superfamily; (2)
BasC showed obligate amino acid exchange activity, which is
characteristic of the catalytic subunits of HATs (Fotiadis et al.,
2013); (3) kinetic and biochemical studies support an asym-
metric binding site in terms of apparent affinity, as reported for
several human LATs (Torras-Llort et al., 2001; Meier et al.,
2002); and (4) both substrate and inhibitor selectivities in
BasC are nearly identical to the eukaryotic LAT subfamily
member Asc-1 (Fukasawa et al., 2000).
The phylogenetic tree of the APC family placed BasC within
the LAT subfamily, and sequence alignments of BasC with the
core members of the human LATs revealed amino acid identities
ranging from 26 to 28% (Fig. 2 and Fig. S1). Additionally, nearly
63% of pathogenic mutations present in LAT transporters are
conserved or semi-conserved in BasC (Fig. S1). This higher SI,
compared with the distant homologues AdiC, ApcT, GadC, and
GkApcT, together with its nearly complete sequence alignment
with hLATs, makes BasC an excellent template for homology
modeling of human transporters. Reliable models of hLAT
transporters would help to unravel the molecular defects un-
derlying pathogenic mutations, as well as identify specific
molecules that regulate LAT activity. In this regard, molecular
docking for ligand discovery in structural models for LAT-
1 based on atomic structures of distantly related prokaryotic
homologues (AdiC and GadC) has produced promising results
(Geier et al., 2013).
BasC is a protein from Carnobacterium sp. AT7, a piezo-
philic strain isolated from the Aleutian trench (Lauro et al.,
2007). Protein adaptation to high pressure is conferred, in
Figure 5. Substrate and inhibitor specificity of BasC
transport activity. (A) BasC substrate specificity.
10 µM [3H]L-serine (1 µCi/µl) influx into BasC-GFP-PLs
containing 4 mM of the indicated individual amino acids
(black bars). Transport was expressed as the percentage
of the transport in BasC-PLs containing 4 mM L-alanine.
10 µM [3H]L-serine (1 µCi/µl) influx into BasC-GFP-PLs
measured in the presence of 5 mM of the indicated
amino acids in the external medium (white bars). Inhi-
bition was expressed as the percentage of the transport
in BasC-GFP-PLs containing 4 mM L-alanine with no cis-
inhibitors. Data are from three experiments with three
replicates per condition. (B) BasC stereoselectivity.
10 µM [3H]L-serine (1 µCi/µl) influx into BasC-PLs
containing 4 mM of the indicated individual L– or D–
amino acids (black bars). Transport was expressed as
the percentage of the transport in BasC-GFP-PLs con-
taining 4 mM L-alanine. 10 µM [3H]L-serine (1 µCi/µl)
influx into BasC-GFP-PLs measured in the presence of
4 mM of the indicated L– or D–amino acids in the ex-
ternal medium (white bars). Inhibition was expressed as
the percentage of transport in BasC-GFP-PLs containing
4 mM L-alanine with no cis-inhibitors. Data are from
three experiments with three replicates per condition.
(C) BasC amino acid derivative specificity. 10 µM [3H]L-
serine (1 µCi/µl) influx into BasC-GFP-PLs containing
4 mM of the indicated individual amino acid derivatives
(black bars). Transport was expressed as the percentage
of transport in BasC-GFP-PLs containing 4 mM
L-alanine. 10 µM [3H]L-serine (1 µCi/µl) influx into BasC-
GFP-PLs measured in the presence of 4 mM of the in-
dicated amino acid derivatives in the external medium
(white bars). Inhibition was expressed as the percentage
of transport in BasC-GFP-PLs containing 4 mM L-alanine
with no cis-inhibitors. Data are from three experiments
with three replicates per condition.
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part, by weaker intramolecular interactions that favor
higher catalytic efficiencies and greater molecular flexibility
(Somero, 1992; Brindley et al., 2008). In this regard, BasC is
an extremely fast and efficient amino acid exchanger. Ad-
ditionally, the lack of intramolecular disulfide bridges, due to
the presence of only one cysteine in the whole BasC amino
acid sequence (Cys 427), is consistent with these adaptations
to high-pressure environments. This particular character-
istic of BasC makes it an excellent model for biochemical
studies involving single cysteine substitutions. In this re-
gard, the single cysteine mutant A20C-C427A (mutant A20C)
used in the present study to address the sidedness of the
substrate’s apparent affinity is a clear example (Fig. 8 and
Fig. 9).
Analysis of BasC in PLs by SDS-PAGE, after HRV-3C protease
treatment, indicated that the protein is integrated into PLs in
two orientations (Fig. 8). Distinct substrate affinities can be
expected for the two orientations (almost two orders of higher
apparent affinity for the external than the cytoplasmic side), as
demonstrated for the reconstituted catalytic subunit (b(0+)AT) of
system b(0+) (Torras-Llort et al., 2001) and for other HATs ex-
pressed in oocytes (Meier et al., 2002). In agreement, fine-
tuning the experimental conditions both outside and inside
BasC-PLs allowed us to calculate two distinct apparent Km values
of 45 ± 5 µM and 2.5 ± 0.4 mM for L-serine, respectively (Fig. 6).
Nevertheless, whether these different affinities corresponded to
the extra- or intracellular sides of the transporter remained
unclear. To address this issue, using a strategy similar to that of
Figure 6. Kinetic characterization of [3H]L-serine uptake in BasC PLs. (A) Determination of extraliposomal kinetic parameters. Michaelis–Menten plot of
the transporter-mediated uptake of [3H]L-serine (1 µCi/µl, 4 s pmol/µg protein · s) in BasC-GFP-PLs containing 4 mM L-alanine, varying extracellular L-serine
concentrations (0–1,500 µM). Mediated transport (exchange) was calculated as [3H]L-serine uptake in PLs containing 4 mM L-alanine minus empty PLs. Data
correspond to a representative experiment, performed using three replicates. Inset: Eadie–Hofstee plot of the kinetics covering only L-serine concentrations
between 0–250 µM (i.e., the high apparent affinity component). Km and Vmax values were 45 ± 5 µM and 6.0 ± 0.2 pmol [3H]L-serine/µg prot · s, respectively.
V/[S]: pmol [3H]L-serine/µg prot · s / substrate concentration. (B) Determination of intraliposomal kinetic parameters. Michaelis–Menten plot of the
transporter-mediated uptake of [3H]L-alanine (10 µM, 1 µCi/µl, pmol/µg protein · s) in BasC-GFP-PLs containing 0.5–10 mM cold L-serine. Mediated transport
was calculated as [3H]L-alanine uptake in L-serine–containing PLs minus empty PLs. Data correspond to a representative experiment, performed using three
replicates. Inset: Eadie–Hofstee plot. Km value was 2.5 ± 0.4 mM. In A and B, three independent experiments were performed, giving similar results. (C)
Extraliposomal kinetics as in A at different intraliposomal concentrations of L-alanine (0.2, 0.5, 1.0, 2.0, and 6.0 mM). Eadie–Hofstee plots from a representative
experiment with the mean values from three replicates. (D) Michaelis–Menten plot of the estimated Vmax values at the different intraliposomal L-alanine
concentrations from the kinetic series shown in C.
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Tsai et al. (2012) developed for the AdiC transporter and
adapted to BasC, we identified that the high-affinity binding
site corresponded to the extracellular site and the low-affinity
one to the intracellular site (Figs. 8 and 9). Interestingly, our
kinetic analysis showed that the substrate extracellular Km
was independent of the concentration of substrate in the cy-
tosolic medium (Fig. 6), suggesting a ping-pong mechanism
compatible with the alternative access model of transport
(Kowalczyk et al., 2011). This is compatible with a binary
complex (one substrate molecule per transporter molecule)
that induces transport, as revealed by the available structures
of APC transporters (Kowalczyk et al., 2011; Wang et al., 2012;
Jungnickel et al., 2018).
This asymmetry in the substrate apparent affinity is a key
feature of mammalian LAT transporters (Torras-Llort et al.,
2001; Meier et al., 2002) that allows them to fulfill their phys-
iological role inmaintaining intracellular amino acid pools in the
mM range while taking up extracellular amino acids at µM
concentrations. The molecular bases underlying this asymmetry
in the substrate apparent affinity of BasC and LATs is at present
unknown. Different substrate binding affinities at both faces of
the transporter and/or impact of different steps of the translo-
cation mechanisms might be at the basis of this asymmetry.
Among the members of the LAT family, BasC showed the
highest substrate and inhibitor selectivity similarity to Asc-1
Figure 7. Extraliposomal and intraliposomal kinetics of BasC without
GFP. (A) Determination of extraliposomal kinetic parameters. Michaelis–
Menten plot of the transporter-mediated uptake of [3H]L-serine (1 µCi, 4 s) in
BasC-PLs containing 4 mM L-alanine, varying extracellular L-serine concen-
trations (0–250 µM). Mediated transport was calculated as [3H]L-serine
uptake in PLs containing 4 mM L-alanine minus empty PLs. Inset: Eadie–
Hofstee plot. Km and Vmax values were 71.7 ± 4.3 µM and 5.7 ± 0.1 pmol [3H]L-
serine/µg prot · s, respectively. (B) Determination of intraliposomal kinetic
parameters. Michaelis–Menten plot of the transporter-mediated uptake of
[3H]L-alanine (10 µM, 1 µCi, 4 s) in BasC-PLs containing 0.5–10 mM cold
L-serine. Mediated transport was calculated as [3H]L-alanine uptake in
L-serine–containing PLs minus empty PLs. In A and B, data correspond to a
representative experiment, performed using three replicates. Inset: Eadie–
Hofstee plot. Km value was 1.3 ± 0.1 mM. Data (mean ± SEM) correspond to
triplicates from representative experiments (A and B).
Figure 8. Vectorial modification of BasC A20C mutant by MTSES from
the extracellular side. (A) Random incorporation of the BasC-GFP protein in
PLs. BasC-GFP-PLs for wild-type and A20C mutant were treated with HRV-
3C protease (3C dig) for 2 h at 4°C. The protease site is accessible in the
inside-out BasC-GFP–inserted molecules, resulting in GFP cleavage.
Protease-treated PLs were then mixed with loading sample buffer and ana-
lyzed in a 10% polyacrylamide gel. As a result, approximately half of the wild-
type and mutant proteins were inserted right-side-out when reconstituted in
E. coli polar lipid liposomes. (B)MTSEA but not MTSES pretreatment of BasC-
A20C-GFP-PLs protected inside-out molecules from Cy5-maleimide dyeing.
BasC-A20C-GFP-PLs were digested with HRV-3C protease for 2 h at 4°C to
remove GFP from the inside-out BasC-A20C molecules. Then, either MTSES
(1 mM; 15min) or MTSEA (5 mM; 30min) pretreatment was performed before
BasC-A20C labeling with the membrane-permeable reagent Cy5-maleimide (1
mM; overnight). Finally, samples were mixed with loading sample buffer and
analyzed in a 10% polyacrylamide gel. In-gel fluorescence at 600 nm (GFP)
and 700 nm (Cy5) is shown. The graph represents quantification of Cy5
fluorescence in BasC-A20C normalized by GFP fluorescence in BasC-A20C-
GFP and relative to aliquots nontreated with MTSES or MTSES in each ex-
periment (NT). Data (mean ± SEM) are from four independent experiments.
Student’s t test for paired data was used for statistical comparison between
NT and MTSES (no significant differences) or MTSEA (***, P ≤ 0.001)
treatments.
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(Fig. 5), thereby suggesting a very similar substrate binding site
design in both cases. In this regard, the extracellular binding site
of Asc1 accepts, although with lower affinity, larger neutral
amino acids (e.g., leucine, isoleucine, and valine), while the in-
tracellular site seems to be strictly designed to recognize small
neutral amino acids (Fukasawa et al., 2000). In contrast, BasC
intra- and extracellular binding sites seem to be restricted to
small neutral amino acids (and asparagine) as uptake of larger
neutral amino acids is negligible. Asc-1, like BasC, is a Na+-
independent amino acid transporter that is noninhibitable by
2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid, and it has a
distinctive property among LATs, namely the capacity to
mediate D-serine uptake (Fukasawa et al., 2000; Fig. 5, A and
B). D-serine is present in the mammalian brain, where Asc-1 is
strongly expressed (Ehmsen et al., 2016) and has been proposed
to be an endogenous modulator of N-methyl-D-aspartate–type
glutamate receptors. Thus, further knowledge of this specific
characteristic shared by Asc-1 and BasC would help elucidate
Figure 9. Sidedness of the transport activity of BasC in PLs. (A and B) Effect of cysteine-modifying reagents MTSES (ES) and MTSEA (EA) on L-serine
transport activity. Time course (0–60 s) influx of 10 µM [3H]L-serine (0.5 µCi/data point) in empty (empty circles) or filled with 4 mM L-alanine (filled circles)
BasC-A20C-GFP-PLs (A) and time course (0–60 s) efflux of 10 µM [3H]L-serine (0.5 µCi/data point) filled BasC-A20C-GFP-PLs against medium without amino
acid (empty circles) or with 4 mM alanine and nontreated (filled circles), treated with 1 mM MTSES (ES) for 15 min (magenta circles), or treated with 5 mM
MTSEA (EA) for 30 min (orange circles; B). 10 µM [3H]L-serine influx and efflux occurs via right-side-out– and inside-out–oriented BasC in PLs, respectively.
MTSES only reaches Cys 20 (C20) in right-side-out–oriented BasC. MTSEA reaches C20 independently of the orientation of BasC insertion in PLs. Influx was
determined by the incorporation of [3H]L-serine into PLs, whereas efflux was determined by the decay of [3H]L-serine remaining in PLs. MTSES or MTSEA
treatment abolished L-serine influx, while only treatment with MTSEA, but not MTSES, completely inhibited L-serine efflux. Data (mean ± SEM) correspond to
quadruplicates of a representative experiment. Two additional independent experiments gave similar results. (C and D) Kinetics of [3H]L-serine/4 mM
L-alanine exchange in BasC-A20C-GFP-PLs treated (magenta circles) and nontreated (black circles) with 1 mMMTSES for 15 min. (D) Eadie–Hofstee plot of the
kinetics shown in C. Nontreated PLs (black circles) showed a complex kinetics with low (line) and high Km components. MTSES treatment abolished the low Km
(i.e., apparent high-affinity) component. Data (mean ± SEM) correspond to quadruplicates of a representative experiment. Another independent experiment
gave similar results.
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pathological situations associated with altered D-serine levels in
the brain (Sason et al., 2017). In this regard, human Asc-1 is
considered a potential target to treat schizophrenia and cognitive
deficits (Fujita et al., 2016; Sakimura et al., 2016).
Little is known about the structure of the light subunits of
HATs (LAT subfamily). The elucidation of their structure is
limited mainly by the low HAT expression in native cells and
tissues and the difficulty to overexpress these proteins in
heterologous systems. The elucidation of the atomic structure
of a prokaryotic transporter with high SI to eukaryotic light
subunits of HATs emerges as an excellent alternative to un-
ravel the molecular mechanisms underlying HATs. To this
end, we have identified, cloned, overexpressed, and purified a
novel prokaryotic Na+-independent neutral amino acid
transporter, BasC, which exhibits the functional properties of
the LAT subfamily. BasC is also the first member of this LAT
subfamily to be crystallized, and analysis of its atomic
structure would help elucidate the amino acid recognition and
translocation mechanisms of LATs, the study of pathological
mutations associated with LAT transporters, and the gener-
ation of reliable models of the hLAT transporters that would
contribute to the intelligent design of more specific and
potent drugs.
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Fernández, E., M. Jiménez-Vidal, M. Calvo, A. Zorzano, F. Tebar, M. Palacı́n,
and J. Chillarón. 2006. The structural and functional units of hetero-
meric amino acid transporters. The heavy subunit rBAT dictates olig-
omerization of the heteromeric amino acid transporters. J. Biol. Chem.
281:26552–26561. https://doi.org/10.1074/jbc.M604049200
Floden, E.W., P.D. Tommaso, M. Chatzou, C. Magis, C. Notredame, and J.M.
Chang. 2016. PSI/TM-Coffee: a web server for fast and accurate mul-
tiple sequence alignments of regular and transmembrane proteins us-
ing homology extension on reduced databases.Nucleic Acids Res. 44(W1):
W339–W343. https://doi.org/10.1093/nar/gkw300
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